| Market Cap | 54.29M | P/E | - | EPS this Y | 9.40% | Ern Qtrly Grth | - |
| Income | -14.65M | Forward P/E | -4.25 | EPS next Y | 20.70% | 50D Avg Chg | 1.00% |
| Sales | 3.23M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
| Dividend | N/A | Price/Book | 2.47 | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 2.92 | Shares Outstanding | 45.73M | 52W Low Chg | 59.00% |
| Insider Own | 59.30% | ROA | -41.78% | Shares Float | 18.90M | Beta | 2.97 |
| Inst Own | 0.66% | ROE | -77.97% | Shares Shorted/Prior | 299.76K/242.70K | Price | 1.19 |
| Gross Margin | 40.26% | Profit Margin | - | Avg. Volume | 163,838 | Target Price | 3.33 |
| Oper. Margin | -272.11% | Earnings Date | - | Volume | 85,366 | Change | 0.00% |
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
